4//SEC Filing
Dearen Danny L. 4
Accession 0001562180-23-003425
CIK 0001603756other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 8:24 PM ET
Size
19.5 KB
Accession
0001562180-23-003425
Insider Transaction Report
Form 4
Axonics, Inc.AXNX
Dearen Danny L.
See Remarks
Transactions
- Exercise/Conversion
Stock Options (Right to buy)
2023-03-31−2,899→ 0 totalExercise: $1.63Exp: 2028-03-30→ Common Stock (2,899 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2023-03-31−6,633→ 15,209 totalExercise: $14.19Exp: 2029-01-30→ Common Stock (6,633 underlying) - Exercise/Conversion
Common Stock
2023-03-31$1.63/sh+2,899$4,725→ 38,993 total - Sale
Common Stock
2023-03-31$54.83/sh−7,198$394,699→ 31,795 total - Exercise/Conversion
Common Stock
2023-03-31$25.82/sh+5,468$141,184→ 36,094 total - Sale
Common Stock
2023-03-31$55.68/sh−7,802$434,404→ 23,993 total - Exercise/Conversion
Common Stock
2023-03-31$14.19/sh+6,633$94,122→ 30,626 total - Exercise/Conversion
Stock Options (Right to buy)
2023-03-31−5,468→ 7,032 totalExercise: $25.82Exp: 2029-12-12→ Common Stock (5,468 underlying)
Footnotes (6)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $54.49 to $55.4839. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $55.49 to $55.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date.
- [F5]The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.
- [F6]The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.
Documents
Issuer
Axonics, Inc.
CIK 0001603756
Entity typeother
Related Parties
1- filerCIK 0001756438
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 8:24 PM ET
- Size
- 19.5 KB